Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06719011 · ClinicalTrials.gov registry record · Phase 1
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
A Phase 1 study of Obesity and Overweight, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 177
- Enrollment target
- 2
- Study locations
NCT06719011 is a Phase 1 study of Obesity and Overweight that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 177 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06719011, a Phase 1 study of Obesity and Overweight, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 177 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine. Participants will either get the new study medicine NNC0174-1213, a study medicine called "cagrilintide" or a placebo (a "dummy medicine" similar to the new study medicine and study medicine but without active ingredients). Which treatment participants will get is decided by chance. The new study medicine and the study medicine are potential new medicines which cannot be prescribed by doctors. This study will last for about a year in total.
Conditions Studied
Interventions
- DRUG NNC0174-1213 A
- DRUG Cagrilintide B
- DRUG Placebo A (NNC0174 1213 A)
Study Locations (2)
Texas
- ICON Early Phase Services, LLC - San Antonio
Utah
- ICON Early Phase Services, LLC - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2024-12-03 |
| Est. Completion | 2026-05-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06719011
The ClinicalTrials.gov registry entry for NCT06719011 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (78% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which NNC0174-1213 A is the first listed.
NCT06719011 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT06719011 about?
NCT06719011 is a clinical study titled "A Study on How NNC0174-1213 Works in People With Overweight or Obesity.". This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine. Participants will either get the new study medicine NNC0174-1213, a study...
What is the current status of trial NCT06719011?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 177 participants. The study started on 2024-12-03. Estimated completion is 2026-05-17.
What conditions does trial NCT06719011 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT06719011?
The interventions under investigation include: NNC0174-1213 A (DRUG), Cagrilintide B (DRUG), Placebo A (NNC0174 1213 A) (DRUG).
Who is sponsoring clinical trial NCT06719011?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06719011 being conducted?
This trial has 2 study locations across Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.